SCHEMBL5312425

SCHEMBL5312425

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)C(OP(=O)(O)OCCN)(C(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)[C@@H](O)CO

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
CNR1 P21554 4/20 0.48
MAPT P10636 3/20 0.48
THRB P10828 2/20 0.48
FAAH O00519 4/20 0.44
MGLL Q99685 2/20 0.44
BLM P54132 2/20 0.44
PLA2G4B P0C869 1/20 0.44
PLA2G4A P47712 1/20 0.44
PLA2G4C Q9UP65 1/20 0.44
CNR2 P34972 3/20 0.43
HPGD P15428 1/20 0.43
S1PR1 P21453 1/20 0.43
GPR55 Q9Y2T6 3/20 0.42
SELP P16109 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
KCNK3 O14649 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7570925 0.97 S1PR1 (0.47) ALDH1A1CNR1MAPTTHRBS1PR1
SCHEMBL18262003 0.94 P2RY10 (0.44) S1PR1TRPV1
SCHEMBL7571747 0.94 P2RY10 (0.44) S1PR1TRPV1
SCHEMBL969822 0.94 P2RY10 (0.44) S1PR1TRPV1
SCHEMBL7573946 0.91 FABP3 (0.42) ALDH1A1CNR1MAPTTHRBBLM
SCHEMBL17144721 0.87 PLA2G2C (0.43)
SCHEMBL37519 0.87 PLA2G2C (0.43)
SCHEMBL19410782 0.87 PLA2G2C (0.43)
SCHEMBL226745 0.87 PLA2G2C (0.43)
SCHEMBL3963403 0.87 PLA2G2C (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023196931-A1 CYCLIC LIPIDS AND LIPID NANOPARTICLES (LNP) FOR THE DELIVERY OF NUCLEIC ACIDS OR PEPTIDES FOR USE IN VACCINATING AGAINST INFECTIOUS AGENTS RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-10-12 WO disclosed
EP-3863645-A1 MODIFIED MRNA FOR THE TREATMENT OF PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS DISORDERS ModernaTX, Inc. (US) 2021-08-18 EP disclosed
WO-2020056370-A1 MODIFIED MRNA FOR THE TREATMENT OF PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS DISORDERS MODERNATX, INC. (US) 2020-03-19 WO disclosed
WO-2007053800-A2 CHARGE-MODIFIED LYSOZYME ANTIMICROBIAL COMPOSITIONS, SURFACTANTS, AND METHODS FOR INFECTIONS AND CYSTIC FIBROSIS THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2007-05-10 WO disclosed
EP-0845981-B1 COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES GENZYME CORP (US) 2002-09-25 EP disclosed
US-5935936-A A DRUG DELIVERY FOR GENE THERAPY COMPRISING A DIAMINO-POLY-ALKYLAMINE-CARBAMOYL CHOLESTEROL AND AT LEAST ONE PHOSPHATIDES GENZYME CORPORATION (US) 1999-08-10 US disclosed
EP-0845981-A1 COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES GENZYME CORPORATION (US) 1998-06-10 EP disclosed
WO-1997046223-A1 COMPOSITIONS COMPRISING CATIONIC AMPHIPHILES AND CO-LIPIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOLECULES GENZYME CORPORATION (US) 1997-12-11 WO disclosed